Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its target price cut by research analysts at Citigroup from $108.00 to $105.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Citigroup‘s price objective would indicate a potential upside of 143.56% from the company’s current price.
A number of other research firms also recently issued reports on ARWR. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Friday, November 13th. Stifel Nicolaus dropped their price target on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, November 13th. HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. UBS Group began coverage on Arrowhead Pharmaceuticals in a report on Thursday, October 15th. They issued a “buy” rating and a $109.00 price objective on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.71.
View Our Latest Stock Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Stock Up 0.3%
Hedge Funds Weigh In On Arrowhead Pharmaceuticals
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $1,208,838,000. Siren L.L.C. boosted its position in Arrowhead Pharmaceuticals by 7.7% during the 1st quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after purchasing an additional 115,000 shares during the period. Jupiter Topco LLC acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at $99,623,000. Janus Henderson Group PLC increased its holdings in Arrowhead Pharmaceuticals by 12.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after purchasing an additional 156,544 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at $70,061,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Further Reading
- Five stocks we like better than Arrowhead Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
